GlassScriptPhysician profile
Jamie L Dodson
NPI 1992106181
$1,447.85
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,428 · 2022: $20.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $335.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $181.08 | 2021 | |
| Amgen INC. | $157.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $120.09 | 2021 | |
| Novo Nordisk INC | $120.05 | 2021 | |
| Lilly USA, LLC | $100.87 | 2021 | |
| Glaxosmithkline, LLC. | $44.95 | 2021 | |
| Radius Health, INC. | $28.75 | 2021 | |
| Merck Sharp & Dohme LLC | $26.41 | 2021 | |
| Biogen, INC. | $24.63 | 2021 | |
| Pfizer INC. | $20.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.05 | 2021 | |
| Eisai INC. | $14.53 | 2021 | |
| Amarin Pharma, INC. | $13.79 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $12.25 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Dodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.